13 Results for "

E17K

" in MedChemExpress (MCE) Product Catalog:
Products (13)

13 Results for "E17K" in MCE Product Catalog:

19
19 Publications Verification
Cat. No.: HY-19719
CAS No.: 1313881-70-7
Synonyms: ARQ-092
Target:  

Akt Parasite

Research Areas:  

Infection Cancer

Miransertib (ARQ-092) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib is effective against Leishmania .
loading...
    loading...
19
19 Publications Verification
Cat. No.: HY-19719A
CAS No.: 1313883-00-9
Synonyms: ARQ-092 hydrochloride
Target:  

Akt Parasite

Research Areas:  

Infection Cancer

Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib hydrochloride is effective against Leishmania .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-137458A
CAS No.: 1416775-08-0
Purity:  99.13%
Synonyms: ARQ 751 trihydrochloride
Target:  

Akt

Research Areas:  

Cancer

Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC50 values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. Vevorisertib trihydrochloride can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-176299
CAS No.: 3034255-93-8
Target:  

Akt

Research Areas:  

Cancer

Tanerasertib (Compound 456) is an AKT1 inhibitor, targerting to AKT1 E17K with the EC50 of 15-60 nM. Tanerasertib can be used in the study of cancer .
loading...
    loading...
Cat. No.: HY-173155
Target:  

Akt

Research Areas:  

Cancer

AKT1-IN-9 (4) is a selective mutant AKT1(E17K) inhibitor, with EC50 values of 9 nM and 995 nM in LAPC4-CR and SkBr3 cells, respectively .
loading...
    loading...
Cat. No.: HY-E70786
Target:  

Akt

Research Areas:  

Cancer

AKT is the oncogenic protein kinase that regulates essential cellular functions such as migration, proliferation, differentiation, apoptosis, and metabolism. Mammalian cells are characterized by the expression of three different Akt isoforms, Akt1, Akt2, and Akt3. AKT1 E17K is a mutant of AKT1. AKT1 E17K Recombinant Human Active Protein Kinase is obtained by expressing AKT1 E17K proteins .
loading...
    loading...
Cat. No.: HY-161438
CAS No.: 3033576-50-7
Target:  

Akt

Research Areas:  

Cancer

Akt1-IN-3 (Compd 7) is an inhibitor of AKT1. Akt1-IN-3 inhibits AKT1- E17K with IC50 < 15 nM .
loading...
    loading...
Cat. No.: HY-161439
CAS No.: 3033577-05-5
Target:  

Akt

Research Areas:  

Cancer

Akt1-IN-4 (Compound 62) is an AKT1-E17K inhibitor with an IC50 value of less than 15 nM .
loading...
    loading...
Cat. No.: HY-19719B
CAS No.: 1817727-88-0
Synonyms: ARQ-092 mesylate
Target:  

Akt Parasite

Research Areas:  

Infection Cancer

Miransertib (ARQ-092) mesylate is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib mesylate is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib mesylate is effective against Leishmania .
loading...
    loading...
Cat. No.: HY-P705727
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: AKT1; v-akt murine thymoma viral oncogene homolog 1; RAC-alpha serine/threonine-protein kinase; AKT; PKB; PRKBA; RAC; PKB alpha; RAC-PK-alpha; proto-oncogene c-Akt; protein kinase B alpha; rac protein kinase alpha; PKB-ALPHA; RAC-ALPHA; MGC99656
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P705728
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: AKT2; v-akt murine thymoma viral oncogene homolog 2; PKBB; PRKBB; PKBBETA; RAC-BETA; AKT2 kinase; rac protein kinase beta; Murine thymoma viral (v-akt) homolog-2; EC 2.7.11.1; RAC-beta serine/threonine-protein kinase; RAC-PK-beta; Protein kinase Akt-2; Protein kinase B, beta; PKB beta
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P705729
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: AKT3; AKT serine/threonine kinase 3; MPPH; PKBG; MPPH2; PRKBG; STK-2; PKB-GAMMA; RAC-gamma; RAC-PK-gamma; RAC-gamma serine/threonine-protein kinase; PKB gamma; RAC-gamma serine/threonine protein kinase; v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma); EC 2.7.11.1
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-183124
CAS No.: 2982897-45-8
Target:  

Akt

Research Areas:  

Cancer

AKT1-IN-12 is a AKT1 inhibitor. AKT1-IN-12 is applicable to research related to breast cancer, colorectal cancer and meningioma .
loading...
    loading...
  • 1